Aug 31, 2023, 18:52
Nitin Jain: Excited to share preclinical data with CRLF2 bispecific antibody for CRLF2-rearranged B-ALL.
Quoting Nitin Jain, the Director of Leukemia CAR-T Program at the MD Anderson Cancer Center:
“Excited to share preclinical data with CRLF2 bispecific antibody for CRLF2-rearranged B-ALL, a high-risk disease subgroup. Development led by ORBIT Platform at MDACC MD Anderson Cancer Center. Marina Konopleva, Jeff Molldrem.“
For the article click here.
Source: Nitin Jain/Twitter